Evidence map›Paper›PMID 26155940›Full record

ArticleOncotarget2015

miR-29b attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2.

Hyun Joo Chung, Young Eun Choi, Eun Sook Kim, Young-Hoon Han, Myung-Jin Park, In Hwa Bae

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Roles of Non-coding RNAs and Angiogenesis in Glioblastoma.Frontiers in cell and developmental biology · 2021
    Review
  11. Review
  12. 2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside modulated human umbilical vein endothelial cells injury under oxidative stress.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2020
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. MicroRNA replacement therapy in cancer.Journal of cellular physiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hyun Joo ChungDivision of Radiation Cancer Research, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
Young Eun ChoiDivision of Radiation Cancer Research, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
Eun Sook KimDivision of Radiation Cancer Research, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
Young-Hoon HanDivision of Radiation Cancer Research, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
Myung-Jin ParkDivision of Radiation Cancer Research, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
In Hwa BaeDivision of Radiation Cancer Research, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
Korea Institute of Radiological and Medical Sciences · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most common malignant brain tumor and exhibits aggressive and invasive behavior. We previously identified four miRNAs-miR-29b, 494, 193a-3p, and 30e-with enhanced expression in GBM following treatment of ionizing radiation by miRNA microarray analysis. In this study, we found that only miR-29b inhibited tumor cell migration and invasion by reducing MMP-2 activity via phospho-AKT/β-catenin signaling, and stimulated a more epithelial-like morphology. Moreover, miR-29b inhibits angiogenesis by attenuating tube formation and the expression of VEGF and Ang-2, and stemness maintenance in GBM cells, as demonstrated by decreasing neurosphere formation and cancer stem cell marker protein expression. These findings support the anti-tumor properties of miR-29b in human GBM cells. Furthermore, miR-29b expression was inversely proportional to that of BCL2L2 mRNA or protein in various cancer cell types. Interestingly, BCL2L2 mRNA is highly expressed in the mesenchymal type of GBM. To further elucidate the relationship between miR-29b and BCL2L2 in GBM, we performed co-transfection reporter assays and determined that miR-29b downregulates BCL2L2 expression by directly binding its 3'UTR. Finally, we confirmed that BCL2L2 repression is of central importance to miR-29b anti-tumor activity using functional assays to examine cell migration, invasion, angiogenesis, and stemness. From these data, we propose that miR-29b may be a useful therapeutic agent in GBM.

Indexed as

Gene Expression Regulation, Neoplastic3' Untranslated RegionsApoptosis Regulatory Proteinsbeta CateninBlood VesselsBlotting, WesternBrain NeoplasmsCell Line, TumorCell MovementCells, CulturedGlioblastomaHumansHuman Umbilical Vein Endothelial CellsMatrix Metalloproteinase 2MCF-7 CellsMicroRNAs3' Untranslated RegionsApoptosis Regulatory ProteinsBCL2L2 protein, humanbeta CateninMatrix Metalloproteinase 2MicroRNAsMIRN29a microRNA, humanProto-Oncogene Proteins c-aktVascular Endothelial Growth Factor ABCL2L2GBMmiR-29bstemnesstumorigenicity

Identifiers

PMID26155940
PMCPMC4621901
OpenAlexW1953327077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.